Treatment of Smoldering Myeloma Cuts Progression Rate in Half

Published Date: 13 Dec 2024

Daratumumab significantly improved PFS, OS, but identity of high-risk population remains elusive

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

2.

Is Exercise an Effective Treatment for Prostate Cancer?

3.

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

4.

Certain Oral Bacteria May Be a Risk Factor for Head and Neck Cancer

5.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot